Suppr超能文献

糖尿病患者尿丙氨酸氨基肽酶的临床评估——AAP微量白蛋白与N-乙酰-β-D-氨基葡萄糖苷酶的比较

[Clinical evaluation of urinary alanine aminopeptidase in the patients with diabetes mellitus-comparison among AAP microalbumin and N-acetyl-beta-D-glucosaminidase].

作者信息

Nakamura S

机构信息

Second Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan.

出版信息

Hokkaido Igaku Zasshi. 1991 Jul;66(4):522-33.

PMID:1680783
Abstract

To determine whether or not urinary Alanine aminopeptidase (AAP) could be used as an early marker for diabetic nephropathy, urinary AAP, microalbumin and N-acetyl-beta-D-glucosaminidase (NAG) were measured in 132 diabetic patients and 59 normal subjects. Urinary AAP, microalbumin and NAG in the diabetic patients and the normal subjects were 15.5 +/- 11.7 U/g. Cr and 9.1 +/- 6.9 (P less than 0.01), 27.4 +/- 35.5 mg/g. Cr and 8.4 +/- 4.4 (P = 0.0001), 10. 3 +/- 9.5 U/g. Cr and 3.9 +/- 2.1 (P = 0.0001), respectively. AAP had a moderate correlation with NAG (r = 0.58, P = 0.0001). AAP, microalbumin and NAG showed a slight positive correlation with age (AAP: r = 0.25, P less than 0.01, microalbumin: r = 0.32, P less than 0.01, NAG: r = 0.21, P less than 0.05), although it is significant, and AAP had a positive correlation with urinary protein concentration (r = 0.45, P = 0.0001) in diabetic patients. However, AAP in diabetic patients without proteinuria was higher than that in age-matched normal subjects. Urinary AAP was correlated with the indices of renal tubular damage like NAG, alpha 1-microglobulin and beta 2-microglobulin, so it seemed to be tubular origin but in the patients with clinical proteinuria, it might be partially glomerular origin. Since urine AAP increased in some patients without microalbuminuria and was not influenced by control of blood sugar, AAP could be used as an early marker of diabetic nephropath y in addition to microalbumin and NAG, but the effect of age should be considered in its estimation as in the case of NAG.

摘要

为了确定尿丙氨酸氨基肽酶(AAP)是否可作为糖尿病肾病的早期标志物,对132例糖尿病患者和59名正常受试者测定了尿AAP、微量白蛋白和N-乙酰-β-D-氨基葡萄糖苷酶(NAG)。糖尿病患者和正常受试者的尿AAP、微量白蛋白和NAG分别为15.5±11.7 U/g·Cr和9.1±6.9(P<0.01)、27.4±35.5 mg/g·Cr和8.4±4.4(P = 0.0001)、10.3±9.5 U/g·Cr和3.9±2.1(P = 0.0001)。AAP与NAG呈中度相关(r = 0.58,P = 0.0001)。AAP、微量白蛋白和NAG与年龄呈轻度正相关(AAP:r = 0.25,P<0.01;微量白蛋白:r = 0.32,P<0.01;NAG:r = 0.21,P<0.05),虽然具有显著性,且糖尿病患者中AAP与尿蛋白浓度呈正相关(r = 0.45,P = 0.0001)。然而,无蛋白尿的糖尿病患者的AAP高于年龄匹配的正常受试者。尿AAP与肾小管损伤指标如NAG、α1-微球蛋白和β2-微球蛋白相关,因此其似乎起源于肾小管,但在临床蛋白尿患者中,可能部分起源于肾小球。由于一些无微白蛋白尿的患者尿AAP升高且不受血糖控制的影响,除微量白蛋白和NAG外,AAP可作为糖尿病肾病的早期标志物,但在评估时应像评估NAG一样考虑年龄的影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验